---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009386"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T05:48:52.276370+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical reports 28% revenue growth in FY2024; guides FY2025 revenue $126M-$130M

## Summary
- Revenue $117.3M FY2024, up 28% YoY; Q4 revenue $31.5M, up 12%.
- Net loss FY2024 $16.4M ($0.12/share) vs prior year net income $660k (incl $11.7M bargain gain).
- Adjusted EBITDA loss FY2024 $2.3M vs loss $1.4M; Q4 positive $438k vs loss $695k.
- Guidance: FY2025 revenue $126M-$130M (7-11% organic growth); expects free cash flow in H2 2025.
- Post-year-end manufacturing/license deal for SimpliGraft: $1.5M upfront, minimum purchase obligations; annualized cost reductions >$5M.

## SEC filing metadata
- accession: 0001493152-25-009386
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315225009386/0001493152-25-009386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315225009386/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009386
- JSON: https://secwatch.observer/filing/0001493152-25-009386.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.